NCT07020169 Using 3D Kidney Model Based on Artificial Intelligence to Assist Partial Nephrectomy: A Prospective Validation Study
| NCT ID | NCT07020169 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Shao Pengfei |
| Condition | Renal Cell Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 232 participants |
| Start Date | 2025-05-01 |
| Primary Completion | 2026-09-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 232 participants in total. It began in 2025-05-01 with a primary completion date of 2026-09-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this study is to develop a real-time artificial intelligence-driven 3D kidney model to assist robotic or laparoscopic partial nephrectomy: • Can this AI-powered model optimize the workflow of partial nephrectomy and enhance surgical benefits?
Eligibility Criteria
Inclusion Criteria: * Ages 18-80 years, regardless of gender * Written informed consent obtained from the patient or legally authorized representative after full protocol disclosure * Preoperative imaging (CT/MRI) confirming clinical stage T1a or select T1b renal tumors suitable for partial nephrectomy (R.E.N.A.L. nephrometry score ≤10) * Localized renal tumors without lymph node/distant metastasis per NCCN Guidelines® (v2023) * Elective minimally invasive partial nephrectomy (laparoscopic/robotic) after comprehensive surgical counseling Exclusion Criteria: * Multifocal renal tumors (bilateral or unilateral) * Prior systemic anticancer therapy (targeted agents/immunotherapy/chemotherapy) within 6 months * Absolute surgical contraindications (e.g., ASA class ≥IV, uncontrolled coagulopathy) * Intraoperative conversion to radical nephrectomy or open approach * Postoperative adjuvant therapy during protocol-defined follow-up (12 months) * Major comorbidities (e.g., NYHA class III/IV heart failure, eGFR \<30 mL/min/1.73m²) affecting outcome assessment * Concurrent enrollment in interventional clinical trials * Investigator-determined ineligibility based on risk-benefit analysis
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07020169 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Renal Cell Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07020169 currently recruiting?
Yes, NCT07020169 is actively recruiting participants. Contact the research team at spf032@hotmail.com for enrollment information.
Where is the NCT07020169 trial being conducted?
This trial is being conducted at Nanjing, China, Nanjing, China.
Who is sponsoring the NCT07020169 clinical trial?
NCT07020169 is sponsored by Shao Pengfei. The trial plans to enroll 232 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.